Category Archives: Mesenchymal Stem Cells

Mol Pharm. Author manuscript; available in PMC 2014 Jan 7. Published in final edited form as: PMCID: PMC3549356 NIHMSID: NIHMS428909 1Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38103 2Department of Endocrinology, University of Tennessee Health Science Center, Memphis, TN 38103 Mesenchymal stem cells (MSCs) are multipotent adult stem cells which have self-renewal capacity and differentiation potential into several mesenchymal lineages including bones, cartilages, adipose tissues and tendons. MSCs may repair tissue injuries and prevent immune cell activation and proliferation. Immunomodulation and secretion of growth factors by MSCs have led to realizing the true potential of MSC-based cell therapy. The use of MSCs as immunomdulators has been explored in cell/organ transplant, tissue repair, autoimmune diseases and prevention of graft vs. host disease (GVHD). This review focuses on the clinical applications of MSC-based cell therapy, with particular emphasis on islet transplantation for treating type I diabetes. Keywords: Mesenchymal stem cells, immunomodulation, islet transplantation, gene delivery, biomaterials Stem cells have self-renewal potential and ability to differentiate into one or more specialized cell types.1 There are two broad types of stem cells, embryonic stem cells (ESCs) and adult stem cells. ESCs are isolated from inner cell mass of blastocyst … Continue reading →

Despite advances in clinical management, cardiovascular disease remains the leading cause of death in America. While cardiomyocytes retain limited plasticity following maturation, the heart is grossly unable to recover from structural damage. Mesenchymal stem cell (MSC) therapy, through its promise of repair and regeneration of cardiac tissue, represents an exciting avenue of treatment for a range of cardiovascular diseases. MSCs are relatively immunoprivileged, lacking both major histocompatibility II and T-cell co-stimulatory signal expression, and possess the unique ability to home into sites of myocardial damage when delivered systemically. Additionally, they have been shown to provide therapeutic benefit via several distinct mechanisms, the most important of which appears to be the abundant secretion of paracrine factors that promote local regeneration. In light of this, several groups have sought to precondition MSCs, using various molecular and genetic means, in order to enhance viability and growth factor secretion in the heart, following transplantation. Here, we analyze and integrate information from recent MSC studies, focusing on underlying mechanisms of MSC-associated repair in animal models of cardiac disease. Additionally, MSC pretreatment studies are organized here to examine their relative effectiveness and potential for clinical use. Data emerging from ongoing human clinical trials are also evaluated … Continue reading →

Regenerative medicine physicians at Minnesota Regenerative Medicine are among only a few in the region to offer stem cell treatments to relieve pain and inflammation associated with osteoarthritis (OA) and chronic tendinitis. Stem Cell therapy at Minnesota Regenerative Medicine refers to the use of an adult patients own stem cells, which are derived from the patients own adipose tissue or bone marrow. During the stem cell harvesting procedure, surgeons use either manual liposuction to extract stem cells from the patients adipose tissue or needle aspiration placed in the pelvic bone to extract stem cells from the patients bone marrow. These stem cells, also called mesenchymal stem cells, are responsible for regenerating and rebuilding the body. Once isolated and concentrated, the stem cells are then injected into the patients damaged joint or tendon using real time fluoroscopy or ultrasound guidance to ensure proper placement. A stem cell treatment represents a complex process that involves multiple steps and takes several hours to perform. Because the stem cell therapy uses the patients own cells, there is no chance of rejection. At Minnesota Regenerative Medicine, strict FDA guidelines in the use of stem cells are followed, and at no time are stem cells manipulated, … Continue reading →

Home Prolotherapy News Stem Cell Therapy for Knee Osteoarthritis and Cartilage Regeneration In this article Ross Hauser, MD discusses research that showsthat stem cell injection therapywill aid in the repair ofarticular cartilageandmeniscus tears and that the treatment relieves symptoms of stiffness,pain, disability, and inability to walk as commonly reported by our patients. Stem Cell Knee Repair: Your surgeons may be anxiously waiting the ability and training to offer stem cellduring surgery- here is the proof: Editorial January 2016 The Journal of Arthroscopic and Related Surgery a publication of theArthroscopy Association of North America. we are believers in stem cell therapy and stem cells have substantial potential to allow 21st century physicians and surgeons to achieve unprecedented tissue healing and repair. Again, additional research is needed to prove the long-term outcomes and the actual cost to society of stem cell treatment for focal defects of the knee. We do believe that it is only a matter of time before the harvesting and growth of stem cells will become cost-effective and commercially available and will be added to our treatment options for restoration of articular cartilage.1 Doctors have long noted that there are limited treatment options for tissue restoration and the prevention … Continue reading →

Journal of Pain Research 2015: 8: 437-447 Introduction: This was a prospective case series designed to investigate treatment for anterior cruciate ligament (ACL) tears using an injection of autologous bone marrow concentrate. Methods: Consecutive adult patients presenting to a private outpatient interventional musculoskeletal and pain practice with knee pain, ACL laxity on exam, and magnetic resonance imaging (MRI) evidence of a grade 1, 2, or 3 ACL tears with less than 1 cm retraction were eligible for this study. Eligible patients were treated with an intraligamentous injection of autologous bone marrow concentrate, using fluoroscopic guidance. Pre- and postprocedural sagittal MRI images of the ACLs were analyzed using ImageJ software to objectively quantify changes between pre- and posttreatment scans. Five different types of measurement of ACL pixel intensity were examined as a proxy for ligament integrity. In addition pain visual analog scale (VAS) and Lower Extremity Functional Scale (LEFS) values were recorded at baseline and at 1 month, 3 months, 6 months, and annually postinjection. Objective outcomes measured were pre- to post-MRI measurement changes, as analyzed by the ImageJ software. Subjective outcomes measured were changes in the VAS and LEFS, and a self-rated percentage improvement. Results: Seven of ten patients showed … Continue reading →

Regenexxspends heavily on innovationand we have a PhD led lab research team and a physician/bio stats led clinical research team to constantly update what we can offer. A couple of years agowe started various projects to determine if we could come up with a way of processing bone marrow that nobody had ever used. Seeking todouble or even triple the number of stem cells extracted in a bone marrow aspiration, we exceeded our own expectations and increasedit 500%+ over what we could do before. Using our previousprocedure, which was already superior to anything else, we could extract about 3-4times thestem cells per cc over what the average automated centrifuge could do. This is important, because these little machines are used by 98% of the physicians performingbone marrow stem cell procedures. There is no real technical expertise required to use these machines. You just place the sample in the machine and push the ON button. Because of this and the fact that these machines are aone-size-fits-all solution to process very different bone marrow samples from very different patients, it wasnt hard to outperform thesedevices. However, our research team investigated many different ways to process marrow. After discarding many, we finally discovered … Continue reading →

Can Diabetes Stem Cell studies help treat patients with Diabetes? Today, new treatments and advances in research are giving new hope to people affected by this disease. The Diabetes Stem Cell studies and treatments are being studied for their efficacy in improving the complications in patients with Type I and Type II Diabetes, through the use of stem cells. These procedures may help patients who dont respond to typical drug treatment. To learn more about becoming a patient and receiving stem cell therapy through StemGenex, please contact one of our patient advocates at (800) 609-7795 or fill out the contact form on this page. Diabetes is a defect in the bodys ability to convert glucose (sugar) to energy. Glucose is the main source of fuel for our body. When food is digested it is changed into fats, protein, or carbohydrates. Foods that affect blood sugars are called carbohydrates. Carbohydrates, when digested, change to glucose. Examples of some carbohydrates are: bread, rice, pasta, potatoes, corn, fruit, and milk products. Individuals with Diabetes should eat carbohydrates but must do so in moderation. Glucose is then transferred to the blood and is used by the cells for energy. In order for glucose to … Continue reading →

Human mesenchymal stem cells (hMSCs) are multipotent adult stem cells present in a variety of tissue niches in the human body. hMSCs have many advantages over other stem cell types due to the broad variety of their tissue sources and for their ability to specifically migrate to tumors and wounds in vivo. hMSCs have become desirable tools in tissue engineering and cell therapy. In most clinical applications hMSCs are expanded in vitro before use. The quality of the culture medium and its performance are particularly crucial with regard to therapeutic applications, since hMSCs properties can be significantly affected by medium components and culture conditions. To date, most of the common culture media for growth and expansion of hMSCs, as well as related reagents (for attachment, dissociation, and cryopreservation), are typically supplemented with serum or other xenogeneic compounds. It is critical that a defined serum-free, xeno-free culture system optimized for hMSCs isolation and expansion is used to greatly facilitate the development of clinically acceptable cell culture processes for reproducibly in generating quality-assured cells. Go here to read the rest: Human Mesenchymal Stem Cells - bioind.com … Continue reading →

Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells,are fibroblast-like cells that demonstrate site-specific differentiation. MSCs may well regenerate damaged or diseased tissues in vivoandplay a potential role in immunomodulation, providing the basis for a variety of clinical applications. Miltenyi Biotec has developed a comprehensive range of research tools and services to support efficient cell isolation, expansion, differentiation, and flow cytometric analysis of MSCs. Explore our solutions to expand your MSC research. Read on: Stem cell product list Stem Cell Products Quick Guide Sample preparation Cell separation Cell analysis Cell culture Molecular applications Whether you work with bone marrow, lipoaspirate, or other sources, Miltenyi Biotec provides you with the rightprotocols, reagents or kits to prepare the samples for downstream experiments. Working with tissues? The gentleMACS Dissociators offer you gentle, automated tissue dissociation to obtain single-cell suspensions with excellent viability. read more Whether you want to isolate MSCs for basic or clinical research, trust in MACS Technology the gold standard in cell separation. Translational research is facilitated with our MicroBeads that cross-react with various small and large-animal species. read more Miltenyi Biotec provides you with optimized kits to standardize your MSC phenotyping, as well as a broad range of antibodies … Continue reading →

Primary Outcome Measures: Patients will be assessed for their capacity to tolerate IV infusion of MSC without acute clinical or physiological deterioration. Vital signs, pulmonary function tests (FEV1 and FCV) and Borg Dyspnea Index will be evaluated. Chest Radiograph, CBC and serum chemistry will be performed. The overall clinical development strategy of this project is to conduct this Phase I dose escalation study entitled "A pilot Study to Evaluate the Safety and Feasibility of Mesenchymal Stem Cells to Induce Remission in Lung Transplant Patients Experiencing Treatment-Refractory Moderate Lung Rejection". This study will be performed under this current IND application and will be limited to the proposed 9 subjects (3 subjects in each of dose escalating subject cohorts). In this application we are proposing to evaluate safety and feasibility of allogeneic, bone marrow (BM) derived mesenchymal stem cells (MSC) to induce remission of moderate treatment refractory bronchiolitis obliterans (BO/BOS). Lung transplant patients with treatment refractory BO/BOS (grade 3) who do not qualify for a second transplant have near 100% mortality or extreme disability. MSCs are multi-potent cells that have the capacity to induce tissue repair and modulate immune response. They have been used successfully in preclinical and clinical studies to treat … Continue reading →